Fig. 8
Cytotoxicity of DOX and CUR formulations in HT-29 cancer cells. a Cell viability of HT-29 cells after treatment with different doses of the non-drug-loaded nanocarriers. b The IC50 comparison of the different drug formulations in HT-29 cells. c Cell viability of HT-29 cells after being exposed to different doses of free drugs, single drug-loaded hydrogel, DOX/CUR-HGs, and DOX/CUR-NGs. Comparison among groups was conducted by one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001